CYP2D6 and chlorpheniramine pharmacokinetics.

被引：0
|
作者：
Yasuda, SU [1 ]
Zannikos, P [1 ]
Young, AE [1 ]
Fried, KM [1 ]
Wainer, JW [1 ]
Woosley, RL [1 ]
机构：
[1] Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2001年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P7 / P7
页数：1
相关论文
共 50 条
  • [1] The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine
    Yasuda, SU
    Zannikos, P
    Young, AE
    Fried, KM
    Wainer, IW
    Woosley, RL
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (05) : 519 - 525
  • [2] EFFECT OF CYP2D6*10 ALLELE ON THE PHARMACOKINETICS OF CHLORPHENIRAMINE IN CHINESE SUBJECTS
    Duan, Yisheng
    Zhong, Dafang
    Zhang, Yifan
    Chen, Xiaoyan
    Wang, Heyao
    DRUG METABOLISM REVIEWS, 2008, 40 : 62 - 62
  • [3] STEREOSELECTIVE INHIBITION OF CYP2D6 BY CHLORPHENIRAMINE
    SALCEDO, JA
    YASUDA, SU
    MURPHY, MP
    WOOSLEY, RL
    FLOCKHART, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (02) : 149 - 149
  • [4] On the impact of the CYP2D6 ultra-rapid metabolizer genotype on mirtazapine pharmacokinetics.
    Brockmöller, J
    Kirchheiner, J
    Henckel, H
    Meineke, I
    Roots, I
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P67 - P67
  • [5] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [6] MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers
    de la Torre, R
    Farré, M
    Mathúna, BO
    Roset, PN
    Pizarro, N
    Segura, M
    Torrens, M
    Ortuño, J
    Pujadas, M
    Camí, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (07) : 551 - 554
  • [7] MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers
    Rafael de la Torre
    Magí Farré
    Brian Ó Mathúna
    Pere N. Roset
    Neus Pizarro
    Mireia Segura
    Marta Torrens
    Jordi Ortuño
    Mitona Pujadas
    Jordi Camí
    European Journal of Clinical Pharmacology, 2005, 61 : 551 - 554
  • [8] Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics
    Saiz-Rodriguez, Miriam
    Ochoa, Dolores
    Roman, Manuel
    Zubiaur, Pablo
    Koller, Dora
    Mejia, Gina
    Abad-Santos, Francisco
    PHARMACOGENOMICS, 2020, 21 (10) : 663 - 675
  • [9] Correlation of endoxifen pharmacokinetics and CYP2D6 genotypes
    Tchu, S. M.
    Wang, P.
    Stone, J.
    Ziv, E.
    Lorizio, W.
    Wu, A.
    CLINICAL CHEMISTRY, 2008, 54 (06) : A167 - A167
  • [10] Effects of the CYP2D6 genotypes on the pharmacokinetics of atomoxetine
    Choi, Chang-Ik
    Bae, Jung-Woo
    Jang, Choon-Gon
    Lee, Seok-Yong
    FASEB JOURNAL, 2011, 25
12345